Erythropoietin use in critically ill patients: Forest and trees

CMAJ. Canadian Medical Association Journal

Volumn 177, Issue 7, 2007, Pages 747-749

  Corwin, Howard L ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; ANTIANEMIC AGENT;

ANEMIA; ANTICOAGULANT THERAPY; BLOOD TRANSFUSION; BURN PATIENT; CELL PROTECTION; CLINICAL FEATURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISEASE COURSE; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; META ANALYSIS; NOTE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; CRITICAL ILLNESS;

ANEMIA; CRITICAL ILLNESS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEMATINICS; HUMANS;

EID: 34748883048     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071150     Document Type: Note

References (15)

1. Zarychanski R, Turgeon AF, McIntyre L, et al. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007; 177(7):725-34.
2. Rodriguez RM, Corwin HL, Gettinger A, et al. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001;16:36-41.
3. Vincent JL, Baron J-F, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002;288:1499-507.
4. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: Anemia and blood transfusion in the critically ill - current clinical practice in the United States. Crit Care Med 2004;32:39-52.
5. Corwin HL, Krantz S. Anemia in the critically ill: "acute" anemia of chronic disease. Crit Care Med 2000;28:3098-9.
6. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double blind placebo controlled trial. Crit Care Med 1999;27:2346-50.
7. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double blind placebo controlled trial. JAMA 2002;288:2827-35.
8. Corwin HL, Gettinger A, Fabian T, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76.
9. Silver M, Bazan A, Corwin HL, et al. A randomized double blind placebo controlled trial of recombinant human erythropoietin in long-term acute care patients. Crit Care Med 2006;34:2310-6.
10. Oxman AD, Guyatt G, Green L, et al. When to believe a subgroup analysis. In: Guyatte G, Rennie D, editors. Users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago: American Medical Association Press; 2002.
11. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5.
12. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo controlled trial. Lancet 2003;362:1255-60.
13. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72.
14. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14.
15. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006;355:2085-98.